Seres Therapeutics (MCRB) Lifted to Sell at BidaskClub

BidaskClub upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a strong sell rating to a sell rating in a research note issued to investors on Friday.

Several other brokerages have also recently weighed in on MCRB. Zacks Investment Research cut shares of Seres Therapeutics from a hold rating to a sell rating in a research note on Wednesday, July 11th. ValuEngine upgraded shares of Seres Therapeutics from a sell rating to a hold rating in a research note on Tuesday, September 4th. Bank of America cut shares of Seres Therapeutics from a neutral rating to an underperform rating in a research note on Friday, August 3rd. Finally, Chardan Capital reiterated a buy rating on shares of Seres Therapeutics in a research note on Sunday, October 28th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $12.13.

Shares of Seres Therapeutics stock opened at $7.52 on Friday. Seres Therapeutics has a twelve month low of $5.64 and a twelve month high of $11.35. The company has a debt-to-equity ratio of 0.85, a quick ratio of 2.76 and a current ratio of 2.76.

In other Seres Therapeutics news, insider John G. Aunins sold 14,279 shares of Seres Therapeutics stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $5.94, for a total value of $84,817.26. Following the completion of the sale, the insider now owns 103,811 shares in the company, valued at approximately $616,637.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Roger Pomerantz sold 12,518 shares of Seres Therapeutics stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $9.10, for a total transaction of $113,913.80. Following the completion of the sale, the insider now owns 218,799 shares of the company’s stock, valued at approximately $1,991,070.90. The disclosure for this sale can be found here. Insiders sold a total of 69,634 shares of company stock valued at $526,006 in the last quarter. Corporate insiders own 37.10% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. bought a new position in Seres Therapeutics in the 2nd quarter valued at about $117,000. Bank of America Corp DE increased its holdings in Seres Therapeutics by 175.0% in the 2nd quarter. Bank of America Corp DE now owns 36,489 shares of the biotechnology company’s stock valued at $314,000 after buying an additional 23,222 shares during the period. A.R.T. Advisors LLC increased its holdings in Seres Therapeutics by 141.3% in the 1st quarter. A.R.T. Advisors LLC now owns 45,952 shares of the biotechnology company’s stock valued at $337,000 after buying an additional 26,909 shares during the period. Chicago Equity Partners LLC bought a new position in Seres Therapeutics in the 2nd quarter valued at about $415,000. Finally, Schwab Charles Investment Management Inc. increased its holdings in Seres Therapeutics by 18.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 117,255 shares of the biotechnology company’s stock valued at $1,009,000 after buying an additional 18,562 shares during the period. Institutional investors and hedge funds own 77.92% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

See Also: Investing strategies using the yield curve

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply